Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Summary
This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)
Detailed description
This two-arm, parallel group-randomized research study is to test a new communication tool (CASI) for people with ovarian cancer, caregivers, and clinicians. This is a pilot feasibility study, which means this is the first time researchers are studying CASI. Clinicians will be randomized into one of the two study groups, Arm 1 or Arm 2, and patients and caregivers will be enrolled in the study arm to which their clinician has been randomized. The research study procedures include screening for eligibility, audio recorded clinic visits, and questionnaires. Participation in this research study is expected to last for up to 12 weeks for patients and caregivers, and for up to 52 weeks for clinicians. It is expected that up to 112 people will take part in this research study, including up to 50 patients, 50 caregivers, and 12 clinicians (six dyads). The National Institute for Nursing Research is supporting this research by providing funding.
Arms & interventions
- BehavioralCollaborative Agenda-Setting Intervention
A collaborative agenda-setting intervention (CASI) to promote patient-centered communication, set agendas for discussion at in-clinic visits, increase discussion of psychosocial concerns, and reduce clinician burden. The intervention is integrated into the patient portal and electronic health record. Prior to a clinic visit, the intervention elicits patients' and caregivers' preferences and concerns, then communicates this information to clinicians. Patients, caregivers, and clinicians receive communication resources, while patients and caregivers receive tailored educational materials and navigation to supportive care services.
Outcome measures
Primary
Enrollment Rate
The proportion of approached participants that are enrolled. Feasibility of an efficacy trial is defined as ≥60% enrollment among approached participants.
Time frame: Pre-consent
Secondary
Acceptability of Intervention
Time frame: Approximately 12 (patient and caregiver participants) and 52 (clinician participants) weeks after enrollment
Proportion of Participant-Rated Intervention Helpfulness
Time frame: Approximately 12 (patient and caregiver participants) and 52 (clinician participants) weeks after enrollment
Proportion of Participant-Rated Intervention Burden
Time frame: Approximately 12 (patient and caregiver participants) and 52 (clinician participants) weeks after enrollment
Change in the Functional Assessment of Cancer Therapy - General (FACT-G) Score from Baseline to 12 Weeks (Arm 1)
Time frame: Baseline and 12 weeks after enrollment
Change in FACT-G Score from Baseline to 12 Weeks (Arm 2)
Time frame: Baseline and 12 weeks after enrollment
Eligibility criteria
Study locations (1)
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215